This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Genome Medicine Open Access 27 June 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Alnylam terminates revusiran program, stock plunges. Nat Biotechnol 34, 1213–1214 (2016). https://doi.org/10.1038/nbt1216-1213
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1216-1213